- Home
- Europe Kirsten Rat Sarcoma Kras Market
Europe Kirsten Rat Sarcoma (KRAS) Market - Industry Trends and Forecast to 2028
- Published Date: September, 2022 | Report ID: CLS-322 | No of pages: 250 | Format:
Europe Kristen Rat Sarcoma (KRAS) market is projected to register a CAGR of 11.8% in the forecast period of 2021 to 2028. The new market report contains data for the historic year 2019, the base year of calculation is 2020 and the forecast period is 2021 to 2028
Market Segmentation:
Europe Kirsten Rat Sarcoma (KRAS) Market, By Product (Reagents and Kits, Analyzers, Consumables), Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Others), Age Group (Adult, Paediatric), Application (Disease Diagnostics, Predictive, Drug Discovery and Development Therapeutic Approach/ Prognostics, Development of Molecular Diagnostics, Research and Development, Personalised Medicine, Others), End User (Diagnostic Laboratories, Hospitals, Pharma & Biotech Companies, Oncology Speciality Clinics, Academic & Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributor), Country (Germany, France, U.K., Italy, Russia, Spain, Switzerland, Netherlands, Turkey, Belgium and Rest of Europe) Industry Trends and Forecast to 2028
Some of the major factors contributing to the growth of the Europe Kirsten Rat Sarcoma (KRAS) market are:
Increase Prevalence of Cancer
High Frequency of KRAS mutation
Market Players:
The key market players for Europe Kirsten Rat Sarcoma (KRAS) market are listed below:
Thermo Fisher Scientific Inc.
F. Hoffmann-La Roche
Biocartis
llumina, Inc.
Merck KGaA
Abbott
QIAGEN
Agilent Technologies, Inc.
TABLE OF CONTENT
TABLE OF CONTENTS 1 INTRODUCTION 1.1 OBJECTIVES OF THE STUDY 1.2 MARKET DEFINITION 1.3 OVERVIEW OF THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET 1.4 CURRENCY AND PRICING 1.5 LIMITATIONS 1.6 MARKETS COVERED 2 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: SEGMENTATION 2.1 MARKETS COVERED 2.2 GEOGRAPHICAL SCOPE 2.3 YEARS CONSIDERED FOR THE STUDY 2.4 DBMR TRIPOD DATA VALIDATION MODEL 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 2.6 MULTIVARIATE MODELLING 2.7 PRODUCT LIFELINE CURVE 2.8 DBMR MARKET POSITION GRID 2.10 MARKET END USER COVERAGE GRID 2.11 SECONDARY SOURCES 2.12 ASSUMPTIONS 3 EXECUTIVE SUMMARY 4 PREMIUM INSIGHTS 5 EPIDERMILOGY 6 PESTEL ANALYSIS 7 PORTERS FIVE 8 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: REGULATORY FRAMEWORK 8.1 THE U.S. REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS) 8.2 CANADA REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS) 8.3 EUROPE REGULATORY GUIDANCE FOR KRISTEN RAT SARCOMA (KRAS) 8.4 JAPAN REGULATORY GUIDANCE FOR KIRSTEN RAT SARCOMA (KRAS) 8.5 AUSTRALIA REGULATORY SCENARIO FOR KIRSTEN RAT SARCOMA (KRAS) 9 MARKET OVERVIEW 9.1 DRIVERS 9.1.1 GROWING PREVALENCE OF CANCER 9.1.2 INCREASING R&D INVESTMENT 9.1.3 HIGH FREQUENCY OF KIRSTEN RAT SARCOMA (KRAS) MUTATION 9.2 RISING SHARE OF AGING POPULATION 9.2.1 PENETRATION OF NOVEL PRODUCTS 9.3 RESTRAINTS 9.3.1 HIGH COST OF PRODUCTS 9.3.2 PRODUCT RECALL IN RECENT PAST 9.3.3 LIMITATION OF KIRSTEN RAT SARCOMA (KRAS) MUTATION TESTING 9.3.4 ADVANCED LABORATORY REQUIREMENT 9.4 OPPORTUNITIES 9.4.1 INCREASING FUNDING FOR CANCER RESEARCH 9.4.2 COLLABORATION BETWEEN PHARMA AND DIAGNOSTIC COMPANIES 9.4.3 HIGH RISK OF KIRSTEN RAT SARCOMA (KRAS) MUTATION IN SPECIFIC POPULATION 9.5 CHALLENGES 9.5.1 LACK OF AWARENESS AND DEARTH OF EXPERTISE 9.5.2 HUGE UNMET MEDICAL NEED FOR KIRSTEN RAT SARCOMA (KRAS) 10 IMPACT OF COVID-19 ON THE EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET 10.1 IMPACT ON PRICE 10.2 IMPACT ON DEMAND 10.3 IMPACT OF SUPPLY 10.4 STRATEGIC DECISIONS BY MANUFACTURERS 10.5 CONCLUSION 11 EUROPE KIRSTEN RAT SARCOMA (KRAS) (KRAS) MARKET (KRAS) MARKET, BY PRODUCT 11.1 OVERVIEW 11.2 REAGENTS AND KITS 11.2.1 PCR TEST KITS 11.2.2 LIQUID BIOPSY PANELS 11.2.3 KRAS MONOCLONAL ANTIBODY 11.2.4 OTHERS 11.3 ANALYZERS 11.4 CONSUMABLES 11.5 CAPILLARY ELECTROPHORESIS POLYMERS 11.6 COLUMNS 11.7 BUFFERS 11.8 ENZYMES 11.9 DNA SIZE MARKER 11.10 MAGNET PLATES 11.11 COLLECTION TUBES 11.12 OTHERS 12 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY CANCER TYPE 12.1 OVERVIEW 12.2 LUNG CANCER 12.3 COLORECTAL CANCER 12.4 PANCREATIC CANCER 12.5 BREAST CANCER 12.6 PROSTATE CANCER 12.7 CERVICAL CANCER 12.8 SKIN CANCER 12.9 KIDNEY CANCER 12.10 BLOOD CANCER 12.11 OTHERS 13 EUROPE KIRSTEN RAT SARCOMA (KRAS) (KRAS) MARKET (KRAS)TREATMENT MARKET, BY AGE GROUP 13.1 OVERVIEW 13.2 ADULTS 13.3 PEDIATRIC 14 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY APPLICATION 14.1 OVERVIEW 14.2 DISEASE DIAGNOSTICS 14.3 PREDICTIVE 14.4 DRUG DISCOVERY AND DEVELOPMENT 14.5 THERAPEUTIC APPROACH OR PROGNOSTICS 14.6 DEVELOPMENT OF MOLECULAR DIAGNOSTICS 14.7 RESEARCH AND DEVELOPMENT 14.8 PERSONALISED MEDICINE 14.9 OTHERS 15 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY END USER 15.1 OVERVIEW 15.2 DIAGNOSTIC LABORATORIES 15.3 HOSPITALS 15.4 PHARMA AND BIOTECH COMPANIES 15.5 ONCOLOGY SPECIALITY CLINICS 15.6 ACADEMIC AND CANCER RESEARCH INSTITUTES 15.7 OTHERS 16 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET, BY DISTRIBUTION CHANNEL 16.1 OVERVIEW 16.2 DIRECT TENDER 16.3 RETAIL SALES 16.4 THIRD PARTY DISTRIBUTOR 17 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET BY COUNTRY 17.1 EUROPE 17.1.1 GERMANY 17.1.2 FRANCE 17.1.3 U.K. 17.1.4 ITALY 17.1.5 RUSSIA 17.1.6 SPAIN 17.1.7 SWITZERLAND 17.1.8 NETHERLANDS 17.1.9 TURKEY 17.1.10 BELGIUM 17.1.11 REST OF EUROPE 18 EUROPE KIRSTEN RAT SARCOMA (KRAS) MARKET: COMPANY LANDSCAPE 18.1 COMPANY SHARE ANALYSIS: EUROPE 19 SWOT ANALYSIS 20 COMPANY PROFILE 20.1 THERMO FISHER SCIENTIFIC INC. 20.1.1 COMPANY SNAPSHOT 20.1.2 REVENUE FINANCIALS 20.1.3 PRODUCT PORTFOLIO 20.1.4 RECENT DEVELOPMENTS 20.2 F.HOFFMANN-LA ROCHE LTD 20.2.1 COMPANY SNAPSHOT 20.2.2 REVENUE ANALYSIS 20.2.3 PRODUCT PORTFOLIO 20.2.4 RECENT DEVELOPMENTS 20.3 BIOCARTIS 20.3.1 COMPANY SNAPSHOT 20.3.2 REVENUE FINANCIALS 20.3.3 PRODUCT PORTFOLIO 20.3.4 RECENT DEVELOPMENTS 20.4 ILLUMINA, INC 20.4.1 COMPANY SNAPSHOT 20.4.2 REVENUE FINANCIALS 20.4.3 PRODUCT PORTFOLIO 20.4.4 RECENT DEVELOPMENTS 20.5 MERCK KGAA 20.5.1 COMPANY SNAPSHOT 20.5.2 REVENUE ANALYSIS 20.5.3 0PRODUCT PORTFOLIO 20.5.4 RECENT DEVELOPMENTS 20.6 ABBOTT 20.6.1 COMPANY SNAPSHOT 20.6.2 REVENUE ANALYSIS 20.6.3 PRODUCT PORTFOLIO 20.6.4 RECENT DEVELOPMENT 20.7 QIAGEN 20.7.1 COMPANY SNAPSHOT 20.7.2 REVENUE ANALYSIS 20.7.3 PRODUCT PORTFOLIO 20.7.4 RECENT DEVELOPMENT 20.8 ALIGENT TECHNOLOGIES, INC. 20.8.1 COMPANY SNAPSHOT 20.8.2 REVENUE ANALYSIS 20.8.3 PRODUCT PORTFOLIO 20.8.4 RECENT DEVELOPMENTS 20.9 AMOY DIAGNOSTICS CO., LTD. 20.9.1 COMPANY SNAPSHOT 20.9.2 PRODUCT PORTFOLIO 20.9.3 RECENT DEVELOPMENT S 20.10 AGENA BIOSCIENCES, INC 20.10.1 COMPANY SNAPSHOT 20.10.2 PRODUCT PORTFOLIO 20.10.3 RECENT DEVELOPMENTS 20.11 BIOTYPE GMBH 20.11.1 COMPANY SNAPSHOT 20.11.2 PRODUCT PORTFOLIO 20.11.3 RECENT DEVELOPMENTS 20.12 CENTOGENE N.V. 20.12.1 COMPANY SNAPSHOT 20.12.2 REVENUE ANALYSIS 20.12.3 PRODUCT PORTFOLIO 20.12.4 RECENT DEVELOPMENTS 20.13 DIACARTA 20.13.1 COMPANY SNAPSHOT 20.13.2 PRODUCT PORTFOLIO 20.13.3 RECENT DEVELOPMENTS 20.14 ENTROGEN, INC. 20.14.1 COMPANY SNAPSHOT 20.14.2 PRODUCT PORTFOLIO 20.14.3 RECENT DEVELOPMENTS 20.15 MIRADX 20.15.1 COMPANY SNAPSHOT 20.15.2 PRODUCT PORTFOLIO 20.15.3 RECENT DEVELOPMENT 20.16 PANAGENE 20.16.1 COMPANY SNAPSHOT 20.16.2 PRODUCT PORTFOLIO 20.16.3 RECENT DEVELOPMENTS 20.17 PROTEINTECH GROUP, INC 20.17.1 COMPANY SNAPSHOT 20.17.2 PRODUCT PORTFOLIO 20.17.3 RECENT DEVELOPMENTS 20.18 SYSMEX INOSTICS 20.18.1 COMPANY SNAPSHOT 20.18.2 PRODUCT PORTFOLIO 20.18.3 RECENT DEVELOPMENTS 20.19 TAKARA BIO, INC 20.19.1 COMPANY SNAPSHOT 20.19.2 REVENUE FINANCIALS 20.19.3 PRODUCT PORTFOLIO 20.19.4 RECENT DEVELOPMENTS 20.20 VIENNALAB DIAGNOSTICS GMBH 20.20.1 COMPANY SNAPSHOT 20.20.2 PRODUCT PORTFOLIO 20.20.3 RECENT DEVELOPMENTS 21 QUESTIONNAIRE 22 RELATED REPORTSSegmentation
Short Description Europe Kirsten Rat Sarcoma (KRAS) Market, By Product (Reagents and Kits, Analyzers, Consumables), Cancer Type (Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Breast Cancer, Prostate Cancer, Cervical Cancer, Skin Cancer, Kidney Cancer, Blood Cancer, Others), Age Group (Adult, Paediatric), Application (Disease Diagnostics, Predictive, Drug Discovery and Development Therapeutic Approach/ Prognostics, Development of Molecular Diagnostics, Research and Development, Personalised Medicine, Others), End User (Diagnostic Laboratories, Hospitals, Pharma & Biotech Companies, Oncology Speciality Clinics, Academic & Cancer Research Institutes, Others), Distribution Channel (Direct Tender, Retail Sales, Third Party Distributor), Country (Germany, France, U.K., Italy, Russia, Spain, Switzerland, Netherlands, Turkey, Belgium and Rest of Europe) Industry Trends and Forecast to 2028 Market Definition: The RAS proteins, originally belonged to the oncogenic products of Harvey and Kirsten rat sarcoma viruses. Three homologous genes code the mammalian RAS proteins. The proto-oncogene for Harvey Ras virus (H-ras), the proto-oncogene for Kirsten Ras virus (K-Ras) and neural Ras (N-ras). These three forms of RAS genes are found in diverse mammalian human specimens. An additional transforming gene was found in the human neuroblastoma and Fibrosarcoma cell lines, which were later identified as a third functional member of the RAS gene family. Market Segmentation: Kirsten Rat Sarcoma (KRAS) market is categorized into six notable segments which are based on the product, cancer type, age group, application, end user and distribution channel. On the basis of product, the Kirsten Rat Sarcoma (KRAS) market is segmented into analyzers, reagents and kits, consumables On the basis of cancer type, the Kirsten Rat Sarcoma (KRAS) market is segmented into breast cancer, colorectal cancer, pancreatic cancer, lung cancer, cervical cancer, prostate cancer, skin cancer, blood cancer, kidney cancer, ovarian cancer and others On the basis of age group, the Kirsten Rat Sarcoma (KRAS) market is segmented into pediatric and adult On the basis of application, the Kirsten Rat Sarcoma (KRAS) market is segmented into development of molecular diagnostics, disease diagnostics, drug discovery and development, personalised medicine, predictive, research and development, therapeutic approach/ prognostics and others On the basis of end user, the Kirsten Rat Sarcoma (KRAS) market is segmented into academic & cancer research institutes, diagnostic laboratories, hospitals, oncology speciality clinics, pharma & biotech companies and others On the basis of distribution channel, the Kirsten Rat Sarcoma (KRAS) market is segmented into direct tenders, retail sales, and third party distributor Market Players The key market players for Europe Kirsten Rat Sarcoma (KRAS) market are listed below: Thermo Fisher Scientific Inc. F. Hoffmann-La Roche Biocartis llumina, Inc. Merck KGaA Abbott QIAGEN Agilent Technologies, Inc.Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.